EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy

Fangfang Li iD, Jing Liu iD, Yunfeng Fu iD

Current Treatment Options in Oncology · 2024-11 · 25 (11) · 1354-1365

DOI: 10.1007/s11864-024-01273-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 21.10.2024. Verfasst von Fangfang Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 131 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Multiple myeloma (MM) is a heterogeneous plasma cell tumor with a survival period of several months to over ten years. Despite the development of various new drugs, MM is still incurable and recurs repeatedly. Bortezomib, a landmark event in the history of MM treatment, has dramatically improved the prognosis of patients with MM. Although proteasome inhibitors (PIs) represented by bortezomib, have greatly prolonged MM survival, unfortunately, almost all MM will develop bortezomib resistance, leading to relapse with a shorter survival. It has been reported that both the tumor microenvironment and myeloma cells drive bortezomib resistance. Multiple treatment methods have been attempted to overcome bortezomib resistance, but unfortunately, there has been no breakthrough. It is believed that the key resistance mechanism has not yet been discovered. A deeper understanding of the mechanism of bortezomib resistance and strategies to overcome it can help identify key resistance mechanisms and further improve the prognosis of MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBortezomibDrug Resistance, NeoplasmAntineoplastic AgentsHumansProteasome InhibitorsTumor MicroenvironmentAntineoplastic Combined Chemotherapy ProtocolsPrognosis

Stichwörter der Autor:innen

BortezomibDrug resistanceMechanismsMultiple myelomaStrategy

Substanzen

BortezomibAntineoplastic AgentsProteasome Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
  • Department of Blood Transfusion, The Third Xiangya Hospital of Central South University, Changsha, 410013, China. fuyunfeng@csu.edu.cn.

ORCID-Profile: Fangfang Li, Jing Liu, Yunfeng Fu

Zitieren

APA

Li, F., Liu, J., & Fu, Y. (2024). Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy. Current Treatment Options in Oncology, 25(11), 1354-1365. https://doi.org/10.1007/s11864-024-01273-6

Vancouver

Li F, Liu J, Fu Y. Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy. Current Treatment Options in Oncology. 2024;25(11):1354-1365. doi:10.1007/s11864-024-01273-6

BibTeX
@article{Li2024,
  author = {Li, Fangfang and Liu, Jing and Fu, Yunfeng},
  title = {Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {11},
  pages = {1354--1365},
  doi = {10.1007/s11864-024-01273-6}
}
Kostenlos starten →